Table 3.

Evaluation result for short-term parameter control between adherence and nonadherence with respect to antihyperglycemic therapy, hypertension control and lipid management

Parameter	Target	Guideline	Groups	Total sample number	Target achievement sample number	Target achievement rate (%)	P value*	Adjusted OR (95% CI)†	Adjusted p value†
HbA1c	<7%	ADA	Adherence	2182	1621	74.29	<0.001	1.46 (1.12 to 1.88)	0.004
			Nonadherence	726	416	57.30		Reference
		Chinese guidelines	Adherence	2136	1592	74.53	<0.001	1.42 (1.09 to 1.85)	0.010
			Nonadherence	774	447	57.75		Reference
BP	<130/80 mm Hg	ADA	Adherence	583	200	34.31	<0.001	1.35 (1.03 to 1.78)	0.029
			Nonadherence	1188	202	17.00		Reference
		Chinese guideline	Adherence	615	203	33.01	<0.001	1.39 (1.08 to 1.79)	0.010
			Nonadherence	1247	207	16.60		Reference
LDL-C	Very-high-risk: <1.8 mmol/L, high-risk: <2.6 mmol/L‡	Chinese guideline	Adherence	374	128	34.22	<0.001	1.18 (0.85 to 1.62)	0.321
			Nonadherence	1402	341	24.32		Reference

*P value was obtained via χ² test.

†Adjusted OR and p value were obtained via generalized estimating equations models to adjust for age, sex, eGFR and corresponding parameters (HbA1c or systolic BP, diastolic BP or LDL-C, TG) measured at baseline or current visit.

‡Very-high-risk: have a definite history of ASCVD; high-risk: diabetic patients without history of ASCVD.

ADA, American Diabetes Association; ASCVD, atherosclerotic cardiovascular disease; BP, blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; LDL-C, lowdensity lipoprotein cholesterol; TG, triglyceride.